A computational workflow for the design of irreversible inhibitors of protein kinases

被引:13
作者
Del Rio, Alberto [1 ]
Sgobba, Miriam [1 ]
Parenti, Marco Daniele [1 ]
Degliesposti, Gianluca [1 ]
Forestiero, Rosetta [1 ]
Percivalle, Claudia [2 ]
Conte, Pier Franco [3 ]
Freccero, Mauro [2 ]
Rastelli, Giulio [1 ]
机构
[1] Univ Modena & Reggio Emilia, Dipartimento Sci Farmaceut, I-41100 Modena, Italy
[2] Univ Pavia, Dipartimento Chim Organ, I-27100 Pavia, Italy
[3] Univ Modena & Reggio Emilia, Dipartimento Oncol & Ematol, I-41100 Modena, Italy
关键词
Protein kinases; ERK2; Irreversible inhibition; Cysteine trap; Michael acceptors; Binding free energy; Molecular dynamics; Generalized amber force field; BINDING FREE-ENERGIES; ACCURATE PREDICTION; AUTOMATED PROCEDURE; CRYSTAL-STRUCTURE; TYROSINE KINASES; MM-PBSA; CANCER; IDENTIFICATION; VALIDATION; MUTATIONS;
D O I
10.1007/s10822-010-9324-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Design of irreversible inhibitors is an emerging and relatively less explored strategy for the design of protein kinase inhibitors. In this paper, we present a computational workflow that was specifically conceived to assist such design. The workflow takes the form of a multi-step procedure that includes: the creation of a database of already known reversible inhibitors of protein kinases, the selection of the most promising scaffolds that bind one or more desired kinase templates, the modification of the scaffolds by introduction of chemically reactive groups (suitable cysteine traps) and the final evaluation of the reversible and irreversible protein-ligand complexes with molecular dynamics simulations and binding free energy predictions. Most of these steps were automated. In order to prove that this is viable, the workflow was tested on a database of known inhibitors of ERK2, a protein kinase possessing a cysteine in the ATP site. The modeled ERK2-ligand complexes and the values of the estimated binding free energies of the putative ligands provide useful indicators of their aptitude to bind reversibly and irreversibly to the protein kinase. Moreover, the computational data are used to rank the ligands according to their computed binding free energies and their ability to bind specific protein residues in the reversible and irreversible complexes, thereby providing a useful decision-making tool for each step of the design. In this work we present the overall procedure and the first proof of concept results.
引用
收藏
页码:183 / 194
页数:12
相关论文
共 33 条
[1]   Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies [J].
Bikker, Jack A. ;
Brooijmans, Natasja ;
Wissner, Allan ;
Mansour, Tarek S. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (06) :1493-1509
[2]   Structure-guided development of affinity probes for tyrosine kinases using chemical genetics [J].
Blair, Jimmy A. ;
Rauh, Daniel ;
Kung, Charles ;
Yun, Cai-Hong ;
Fan, Qi-Wen ;
Rode, Haridas ;
Zhang, Chao ;
Eck, Michael J. ;
Weiss, William A. ;
Shokat, Kevan M. .
NATURE CHEMICAL BIOLOGY, 2007, 3 (04) :229-238
[3]   Rapid estimation of relative protein-ligand binding affinities using a high-throughput version of MM-PBSA [J].
Brown, Scott P. ;
Muchmore, Steven W. .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (04) :1493-1503
[4]  
Case D.A., 2006, AMBER
[5]   The Amber biomolecular simulation programs [J].
Case, DA ;
Cheatham, TE ;
Darden, T ;
Gohlke, H ;
Luo, R ;
Merz, KM ;
Onufriev, A ;
Simmerling, C ;
Wang, B ;
Woods, RJ .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) :1668-1688
[6]   Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J].
Cohen, MS ;
Zhang, C ;
Shokat, KM ;
Taunton, J .
SCIENCE, 2005, 308 (5726) :1318-1321
[7]   Activity Prediction and Structural Insights of Extracellular Signal-Regulated Kinase 2 Inhibitors with Molecular Dynamics Simulations [J].
Del Rio, Alberto ;
Baldi, Benedetta Frida ;
Rastelli, Giulio .
CHEMICAL BIOLOGY & DRUG DESIGN, 2009, 74 (06) :630-635
[8]   PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Gale, Christopher-Michael ;
Lifshits, Eugene ;
Gonzales, Andrea J. ;
Shimamura, Takeshi ;
Zhao, Feng ;
Vincent, Patrick W. ;
Naumov, George N. ;
Bradner, James E. ;
Althaus, Irene W. ;
Gandhi, Leena ;
Shapiro, Geoffrey I. ;
Nelson, James M. ;
Heymach, John V. ;
Meyerson, Matthew ;
Wong, Kwok-Kin ;
Janne, Pasi A. .
CANCER RESEARCH, 2007, 67 (24) :11924-11932
[9]   Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors [J].
Ferrari, Anna Maria ;
Degliesposti, Gianluca ;
Sgobba, Miriam ;
Rastelli, Giulio .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (24) :7865-7877
[10]   Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors [J].
Katayama, Naoko ;
Orita, Masaya ;
Yamaguchi, Tomohiko ;
Hisamichi, Hiroyuki ;
Kuromitsu, Sadao ;
Kurihara, Hiroyuki ;
Sakashita, Hitoshi ;
Matsumoto, Yuzo ;
Fujita, Shigeo ;
Niimi, Tatsuya .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 73 (04) :795-801